Update On Phase 3 Librexia ACS Trial
RefinitivMoins d'1 minute de lecture
Bristol-Myers Squibb Co 
BMY:
UPDATE ON PHASE 3 LIBREXIA ACS TRIAL
BRISTOL-MYERS SQUIBB CO - LIBREXIA ACS TRIAL DISCONTINUED DUE TO EFFICACY CONCERNS
BRISTOL-MYERS SQUIBB CO - NO NEW SAFETY CONCERNS IDENTIFIED FOR MILVEXIAN
BRISTOL-MYERS SQUIBB CO - LIBREXIA AF AND STROKE STUDIES CONTINUE, DATA EXPECTED 2026
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Connectez-vous ou créez un compte gratuit à vie pour lire ces nouvelles